ELVN Enliven Therapeutics, Inc.
Healthcare$41.54-1.68%ClosedMarket Cap: $2.53B
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
5.75
P/S
0.00
EV/EBITDA
-21.67
DCF Value
$1.70
FCF Yield
-2.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-21.0%
ROA
-21.2%
ROIC
-25.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-27.8M | $-23.6M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-34.3M | $-29.7M | $— | — |
| FY null | $0.00 | -Infinity% | $-119.7M | $-103.7M | $— | — |
| Q3 null | $0.00 | NaN% | $-25.1M | $-20.1M | $— | — |
| Q2 null | $0.00 | NaN% | $-28.6M | $-25.3M | $— | — |
| Q1 null | $0.00 | NaN% | $-31.7M | $-28.5M | $— | — |
| Q4 null | $0.00 | NaN% | $-26.9M | $-23.2M | $— | — |
| FY null | $0.00 | NaN% | $-104.6M | $-89.0M | $— | — |
| Q3 null | $0.00 | NaN% | $-27.1M | $-23.2M | $— | — |
| Q2 null | $0.00 | NaN% | $-24.6M | $-19.9M | $— | — |
| Q1 null | $0.00 | NaN% | $-26.0M | $-22.7M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-22.7M | $-19.4M | $-0.47 | — |